Diligence memo · auto-generated · as of July 2, 2026

Pattern Bioscience, Inc.

Pattern Bioscience, Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 1.9× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

Pattern Bioscience, Inc. operates in Biotechnology, based in AUSTIN.

Sub-sector tags: biotech.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pattern Bioscience, Inc. has raised $84M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $44M on 2025-07-31.

Most recent recorded round closed around 2025-07-31.

Valuation (modeled)modeled

Provath models Pattern Bioscience, Inc. at approximately $261M (range $137M–$342M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.36× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era. Within the normal band (136% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 18 months.

Last raise 11 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 1.9× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 88% of Biotechnology peers (4293 compared).

Modeled value ranks above 75% of those peers.

Closest niche peers: Newleos Therapeutics, Inc., Biolinq Inc, Atsena Therapeutics, Inc., Galvanize Therapeutics, Inc., X4 Pharmaceuticals, Inc.

Peoplefiled

16 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.